BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/24/2020 7:33:17 AM | Browse: 570 | Download: 939
 |
Received |
|
2020-03-19 05:17 |
|
Peer-Review Started |
|
2020-03-19 05:20 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-04-07 23:42 |
|
Revised |
|
2020-04-24 05:31 |
|
Second Decision |
|
2020-06-03 09:27 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-06-03 23:47 |
|
Articles in Press |
|
2020-06-03 23:47 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-06-19 03:19 |
|
Publish the Manuscript Online |
|
2020-06-24 07:33 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Case Report |
| Article Title |
Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Satoshi Komiyama, Kazushi Numata, Satoshi Moriya, Hiroyuki Fukuda, Makoto Chuma and Shin Maeda |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Kazushi Numata, MD, PhD, Associate Professor, Gastroenterological Center, Yokohama City University Medical Center, 4-57 Urafunecho, Minami-ku, Yokohama 2320024, Kanagawa, Japan. kz-numa@urahp.yokohama-cu.ac.jp |
| Key Words |
Hepatocellular carcinoma; Lenvatinib; Modified Response Evaluation Criteria in Solid Tumors; Main portal vein tumor thrombus; High tumor burden; Case report |
| Core Tip |
We present two cases of unresectable hepatocellular carcinoma with a tumor thrombus in the main portal vein and a high tumor burden accompanied by a tumor diameter > 100 mm. Despite the aforementioned poor prognostic factors, due to the well-preserved liver function, we elected to treat both patients with lenvatinib in the hope of obtaining tumor shrinkage, based on the REFLECT trial. Lenvatinib was demonstrated to be safe, and good therapeutic responses were obtained. Thus, even in the presence of poor prognostic factors, if the liver function is well-preserved, lenvatinib can be effective and safe in patients with unresectable hepatocellular carcinoma. |
| Publish Date |
2020-06-24 07:33 |
| Citation |
Komiyama S, Numata K, Moriya S, Fukuda H, Chuma M, Maeda S. Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports. World J Clin Cases 2020; 8(12): 2574-2584 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i12/2574.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i12.2574 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
